JPH06506824A - モノクロナール抗体 - Google Patents
モノクロナール抗体Info
- Publication number
- JPH06506824A JPH06506824A JP3518457A JP51845791A JPH06506824A JP H06506824 A JPH06506824 A JP H06506824A JP 3518457 A JP3518457 A JP 3518457A JP 51845791 A JP51845791 A JP 51845791A JP H06506824 A JPH06506824 A JP H06506824A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- monoclonal antibody
- cells
- monoclonal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Optics & Photonics (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (20)
- 1.細胞表面の抗原に対して特異性を持つモノクローナル抗体を産生するハイブ リドーマであって、該抗体が霊長類の正常細胞、培養されたヒトの悪性細胞系、 およびヒトの腫瘍に発現することを特徴とし、該抗原が培養基または血漿に流れ 込まない上記ハイブリドーマ。
- 2.細胞表面の抗原に特異性を持ち、且つ免疫グロブリンGクラスであるモノク ロナール抗体であって、該抗原が霊長類の正常細胞、培養されたヒトの悪性細胞 系、およびヒトの腫瘍に発現することを特徴とし、該抗原が培養基または血漿に 流れ込まない上記モノクローナル抗体。
- 3.上記培養ヒト悪性細胞系がOVCAR−2、OVCAR−3、OVCAR− 4、1847、HTB77、HeLa S3、KB、AGSおよびHTB103 からなる群より選ばれることを特徴とする請求項1に記載のハイブリドーマ。
- 4.上記ヒト培養悪性細胞系がOVCAR−2、OVCAR−3、OVCAR− 4、1847、HTB77、HeLa S3、KB、AGSおよびHTB103 からなる群より選ばれることを特徴とする請求項2に記載のモノクロナール抗体 。
- 5.上記ヒト腫瘍が卵巣癌、食道癌または子宮頸部癌に由来する請求項1に記載 のハイブリドーマ。
- 6.上記ヒト腫瘍が卵巣癌、食道癌または子宮頸癌に由来する請求項2に記載の モノクロナール抗体。
- 7.上記霊長類正常組織が中皮である請求項1に記載のハイブリドーマ。
- 8.上記霊長類正常組織が中皮である請求項2に記載のモノクロナール抗体。
- 9.寄託番号がATCC HB 10570のハイブリドーマ細胞系。
- 10.請求項1に記載のハイブリドーマによって産生されるモノクロナール抗体 。
- 11.上記抗体がK1であることを特徴とする請求項2に記載のモノクロナール 抗体。
- 12.請求項2に記載のモノクロナール抗体の複合体の癌の治療への使用。
- 13.上記癌が卵巣癌である請求項12に記載の使用。
- 14.上記抗体が毒素、放射能同位元素または化学療法剤と複合している請求項 12に記載の使用。
- 15.上記抗体が細胞の殺傷を仲介するように修飾されている請求項12に記載 の使用。
- 16.請求項2に記載のモノクロナール抗体の癌の診断への使用。
- 17.上記モノクロナール抗体が放射能標識を付されている請求項16に記載の 使用。
- 18.放射能標識の存在を視覚化することにより診断する請求項16に記載の使 用。
- 19.癌の成長を阻止するに充分な濃度の請求項2に記載のモノクロナール抗体 と医薬的に許容できる担体を含有して成る医薬組成物。
- 20.患者から組織または体液サンプルを採取し、請求項2に記載のモノクロナ ール抗体を該サンプルに添加し、該サンプル中の抗体の存在を視覚化することを 特徴とする請求項2に記載のモノクロナール抗体の癌の診断への使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59629190A | 1990-10-12 | 1990-10-12 | |
US596,291 | 1990-10-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06506824A true JPH06506824A (ja) | 1994-08-04 |
JP2660241B2 JP2660241B2 (ja) | 1997-10-08 |
Family
ID=24386742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3518457A Expired - Lifetime JP2660241B2 (ja) | 1990-10-12 | 1991-10-09 | モノクロナール抗体 |
Country Status (10)
Country | Link |
---|---|
US (3) | US5320956A (ja) |
EP (1) | EP0554356B1 (ja) |
JP (1) | JP2660241B2 (ja) |
AT (1) | ATE171207T1 (ja) |
AU (1) | AU648363B2 (ja) |
CA (1) | CA2093928C (ja) |
DE (1) | DE69130224T2 (ja) |
DK (1) | DK0554356T3 (ja) |
ES (1) | ES2121792T3 (ja) |
WO (1) | WO1992007081A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007197439A (ja) * | 1996-01-05 | 2007-08-09 | Usa Government | 中皮抗原及びそれを標的化するための方法及びキット |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5242813A (en) * | 1990-10-12 | 1993-09-07 | The United States Of America As Represented By The Department Of Health And Human Services | Mouse monoclonal antibodies specific for normal primate tissue, malignant human cultural cell lines human tumors |
SE9501302D0 (sv) * | 1995-04-07 | 1995-04-07 | Bioinvent Internatioal Ab | Antibodies for use in cancertherapy and diagnosis |
US5871941A (en) * | 1995-07-28 | 1999-02-16 | Univ British Columbia | Method of testing expression of CA125 antigen in cultured ovarian surface epithelial cells to identify and monitor individuals having a predisposition to develop ovarian cancer |
US7375183B1 (en) * | 1996-01-05 | 2008-05-20 | The United States Of America As Represented By The Department Of Health And Human Services | Mesothelin, immunogenic peptides derived therefrom, and compositions comprising mesothelin, or immunogenic peptides thereof |
US6406917B1 (en) | 1996-06-11 | 2002-06-18 | Advanced Research And Technology Institute | Methods and compositions for the use of apurinic/apyrimidinic endonucleases |
US5919643A (en) * | 1996-06-11 | 1999-07-06 | Advanced Research & Technology Institute | Methods and compositions for the use of apurinic/apyrimidinic endonucleases |
WO1999028471A2 (en) * | 1997-12-01 | 1999-06-10 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | ANTIBODIES, INCLUDING Fv MOLECULES, AND IMMUNOCONJUGATES HAVING HIGH BINDING AFFINITY FOR MESOTHELIN AND METHODS FOR THEIR USE |
US6809184B1 (en) | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
US7745159B2 (en) * | 1999-02-26 | 2010-06-29 | Nathalie B Scholler | Methods and compositions for diagnosing carcinomas |
US6770445B1 (en) | 1999-02-26 | 2004-08-03 | Pacific Northwest Research Institute | Methods and compositions for diagnosing carcinomas |
DE60028361T2 (de) * | 1999-02-26 | 2007-05-10 | Pacific Northwest Research Institute, Seattle | Verfahren und zusammensetzungen zur karzinomdiagnose |
CA2374398C (en) | 1999-05-27 | 2011-03-15 | Ira Pastan | Immunoconjugates having high binding affinity |
US6987024B1 (en) * | 2000-04-10 | 2006-01-17 | Raven Biotechnologies, Inc. | Human ovarian mesothelial cells and methods of isolation and uses thereof |
US20090110702A1 (en) | 2002-07-12 | 2009-04-30 | The Johns Hopkins University | Mesothelin Vaccines and Model Systems and Control of Tumors |
AU2003259109A1 (en) * | 2002-07-12 | 2004-02-02 | The Johns Hopkins University | Mesothelin vaccines and model systems |
US9200036B2 (en) | 2002-07-12 | 2015-12-01 | The Johns Hopkins University | Mesothelin vaccines and model systems |
US20040180387A1 (en) | 2003-03-13 | 2004-09-16 | Fujirebio Diagnostics, Inc. | Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer |
EP1716168A4 (en) * | 2004-01-21 | 2009-06-24 | Fujirebio America Inc | DETECTION OF PEPTIDES RELATING TO THE FACTOR FOR THE POTENTIATION OF URINARY MESOTHELIN- / MEGACARYOCYTES FOR THE EVALUATION OF MESOTHELIOMA |
WO2005072341A2 (en) | 2004-01-21 | 2005-08-11 | Fujirebio America, Inc. | Detection of mesothelin-/megakaryocyte potentiating factor-related peptides in peritoneal fluid for assessment of the peritoneum and the peritoneal cavity |
WO2005080431A2 (en) | 2004-02-12 | 2005-09-01 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
WO2006005065A2 (en) * | 2004-06-30 | 2006-01-12 | University Of South Florida | Luminescence characterization of quantum dots conjugated with biomarkers for early cancer detection |
AU2006223301B2 (en) | 2005-03-10 | 2010-11-04 | Eisai, Inc. | Anti-mesothelin antibodies |
CA2607444C (en) | 2005-04-22 | 2015-03-10 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
EA018396B1 (ru) | 2007-10-01 | 2013-07-30 | Бристоль-Мейерз Сквибб Компани | Антитела человека, которые связывают мезотелин, и применение таких антител |
BR112013014527A2 (pt) | 2010-12-20 | 2017-03-07 | Genentech Inc | anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, uso do imunoconjugado, método para tratamento de um indivíduo que tem um câncer positivo para mesotelina, para inibição de proliferação de uma célula positiva para mesotelina, para detecção de mesotelina humana em uma amostra biológica e para detectar um câncer positivo para mesotelina |
WO2015123654A1 (en) | 2014-02-17 | 2015-08-20 | The Cleveland Clinic Foundation | Amine passivated nanoparticles for cancer treatment and imaging |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666845A (en) * | 1983-12-16 | 1987-05-19 | Sloan-Kettering Institute | Monoclonal antibodies to ovarian, cervical and uterine human cancers and method of diagnosis |
US4806494A (en) * | 1986-07-24 | 1989-02-21 | The United States Of America As Represented By The Department Of Health & Human Services | Monoclonal antibody against ovarian cancer cells (OVB-3) |
JPH0763389B2 (ja) * | 1986-10-28 | 1995-07-12 | 協和醗酵工業株式会社 | 抗ヒト中皮細胞単クローン性抗体 |
WO1989001629A1 (en) * | 1987-08-19 | 1989-02-23 | Centocor, Inc. | Human ovarian tumor-associated antigen specific for monoclonal antibody ov-tl3 |
US5242813A (en) * | 1990-10-12 | 1993-09-07 | The United States Of America As Represented By The Department Of Health And Human Services | Mouse monoclonal antibodies specific for normal primate tissue, malignant human cultural cell lines human tumors |
-
1991
- 1991-10-09 AT AT91919959T patent/ATE171207T1/de not_active IP Right Cessation
- 1991-10-09 ES ES91919959T patent/ES2121792T3/es not_active Expired - Lifetime
- 1991-10-09 AU AU89219/91A patent/AU648363B2/en not_active Expired
- 1991-10-09 CA CA002093928A patent/CA2093928C/en not_active Expired - Lifetime
- 1991-10-09 EP EP91919959A patent/EP0554356B1/en not_active Expired - Lifetime
- 1991-10-09 JP JP3518457A patent/JP2660241B2/ja not_active Expired - Lifetime
- 1991-10-09 DK DK91919959T patent/DK0554356T3/da active
- 1991-10-09 DE DE69130224T patent/DE69130224T2/de not_active Expired - Lifetime
- 1991-10-09 WO PCT/US1991/007227 patent/WO1992007081A2/en active IP Right Grant
-
1992
- 1992-11-16 US US07/977,727 patent/US5320956A/en not_active Expired - Lifetime
-
1994
- 1994-05-06 US US08/239,101 patent/US5525337A/en not_active Expired - Lifetime
-
1996
- 1996-04-08 US US08/629,053 patent/US5817313A/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007197439A (ja) * | 1996-01-05 | 2007-08-09 | Usa Government | 中皮抗原及びそれを標的化するための方法及びキット |
Also Published As
Publication number | Publication date |
---|---|
US5525337A (en) | 1996-06-11 |
CA2093928A1 (en) | 1992-04-13 |
DE69130224D1 (de) | 1998-10-22 |
ES2121792T3 (es) | 1998-12-16 |
DK0554356T3 (da) | 1999-06-14 |
WO1992007081A2 (en) | 1992-04-30 |
US5320956A (en) | 1994-06-14 |
DE69130224T2 (de) | 1999-05-06 |
AU8921991A (en) | 1992-05-20 |
CA2093928C (en) | 2000-02-29 |
AU648363B2 (en) | 1994-04-21 |
EP0554356A1 (en) | 1993-08-11 |
EP0554356B1 (en) | 1998-09-16 |
ATE171207T1 (de) | 1998-10-15 |
JP2660241B2 (ja) | 1997-10-08 |
US5817313A (en) | 1998-10-06 |
EP0554356A4 (en) | 1993-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06506824A (ja) | モノクロナール抗体 | |
Edwards et al. | Monoclonal antibody identification and characterization of a M r 43,000 membrane glycoprotein associated with human breast cancer | |
Brown et al. | Tumor-specific genetically engineered murine/human chimeric monoclonal antibody | |
AU650302B2 (en) | Mouse monoclonal antibodies | |
JPH03504436A (ja) | Tag‐72及びヒト癌腫に対して結合特異性を有する第二世代モノクローナル抗体及びその使用方法 | |
JPH06509641A (ja) | モノクローナル抗体oxa及びoxbを用いた卵巣癌及び子宮内膜癌の診断法 | |
JP2008535865A (ja) | 抗psmaコンジュゲート抗体 | |
JPS62220197A (ja) | ヒト非小細胞肺癌および一定の他のヒト癌腫に対する単クロ−ン性抗体および抗原 | |
CN101189266A (zh) | 显示cd63表面表达的细胞毒性介导 | |
JP3284133B2 (ja) | ヒト乳脂肪小球膜ムチン抗原の糖タンパク質を確認する単クローン性抗体 | |
AU617652B2 (en) | Monoclonal paratopic molecule directed to human ganglioside gd2 | |
CN101193912B (zh) | 急性白血病和淋巴母细胞性淋巴瘤特异的cd43表位及其用途 | |
USRE40535E1 (en) | Anti-KC4 humanized monoclonal antibody and cells that express the antibody | |
JP3513173B2 (ja) | モノクローナル抗−ガングリオシド抗体、その製造およびそれを含有する腫瘍治療剤 | |
JP2792651B2 (ja) | ヒト膵臓癌に対するモノクローナル抗体 | |
EP0548070B1 (en) | Monoclonal antibody for differentiation of squamous cell carcinoma antigens and method of use for same | |
JPH03240498A (ja) | 抗体およびそれを使用した免疫分析方法 | |
EP0243058B1 (en) | A tumor associated antigen | |
CA2028024A1 (en) | Tumor-associated antigen | |
AU625856B2 (en) | Second generation monoclonal antibodies having binding specificity to tag-72 and human carcinomas and methods for employing the same | |
Colnaghi | Use of bifunctional monoclonal antibodies for retargeting human lymphocytes against ovarian carcinoma cells | |
WO1994003629A1 (en) | Monoclonal antibodies specific for 3',6'-isold1 ganglioside | |
JPH02500405A (ja) | ヒトのガングリオシドgd2に対するモノクローナル・パラトピック分子 | |
IL84466A (en) | A hybrid mouse of the sea-1 and a diagnostic antibody produced thereby |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080613 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090613 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090613 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100613 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100613 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110613 Year of fee payment: 14 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120613 Year of fee payment: 15 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120613 Year of fee payment: 15 |